Biogen's new MS drug shines in market debut

[riky]

Biogen's new MS drug shines in market debut

By Bill Berkrot (Reuters) - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera had surpassed Wall Street's most bullish forecasts, raising expectations that it will eventually become the dominant oral MS treatment. In its first quarter on the market, Tecfidera posted sales of $192 million, including inventory stocking. Biogen said about $110 million of the total represented underlying patient demand. Analysts had expected about $66 million, with the more bullish forecasts at about $90 million. ...

Source: You are not allowed to view links. Register or Login